• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

    2/6/25 8:30:00 AM ET
    $EXAS
    $GE
    $GMED
    $XRAY
    Medical Specialities
    Health Care
    Consumer Electronics/Appliances
    Technology
    Get the next $EXAS alert in real time by email

    CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025.

    Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. Barber will be joining the Board's Science and Technology Committee and Mr. Scavilla will be joining the Board's Audit and Finance Committee.

    "We are pleased to welcome Mike and Dan, two proven leaders with skillsets that are additive to the expertise already represented on our Board and that will be extremely valuable as we continue to execute our transformation strategy," said Greg Lucier, Chairman of the Board. "The Board regularly reviews our composition against our strategic priorities, and we believe that adding broad healthcare experience, as well as deep innovation, technology, finance and operational capabilities, will help Dentsply Sirona realize our vision of transforming dentistry to improve oral health globally as the industry continues to evolve. As we move forward, the Board will continue to actively and regularly evaluate all opportunities to drive durable, profitable growth and enhanced shareholder value."

    Mr. Barber said, "With Dentsply Sirona's long heritage of innovation leadership in the global dental industry, I recognize the Company's tremendous potential, and I am eager to contribute to advance its mission. I appreciate the Board's confidence and look forward to working collaboratively with the rest of the Board and the management team to capitalize on the many opportunities ahead."

    Mr. Scavilla said, "I am honored to join the Board and continue to drive forward Dentsply Sirona's mission of transforming and advancing innovation. As a longtime executive in the healthcare industry, I look forward to bringing my insights and experience to support the Company's strategic growth."

    The Company also announced today that Dr. Dorothea Wenzel has informed the Board of her decision to resign, effective February 5, 2025, due to the increased demands of her recently announced chair nomination.

    "On behalf of the Board and management team, I want to thank Dorothea for her contributions to our Company," Mr. Lucier said. "The Board has benefitted greatly from her expertise and guidance, and we appreciate all she has done to help position Dentsply Sirona for the future."

    Dr. Wenzel added, "It has been an honor to serve on the Board over the last few years. I'm confident in the Board and management team's ability to deliver on the Company's strategy and drive long-term growth and profitability."

    With these changes, the Board has increased in size from 10 to 11 members. In the last two years, the Board has added four highly qualified members and will continue to refresh the Board to ensure the requisite skills to support the transformation of dentistry.

    About Michael Barber

    Mr. Barber has over 40 years of experience in executive positions with General Electric (NYSE:GE), featuring roles within operations, human capital, engineering, strategy, product management, and international P&L leadership. He has successfully launched transformational technologies and products to the market in the fields of diagnostic imaging and point-of-care technology. Mr. Barber also serves on the Board of Directors of Exact Sciences, Inc. (NASDAQ:EXAS) and as a member of the Executive Committee of the Green Bay Packers Football Club and the Board of Regents at the Milwaukee School of Engineering. He previously served on the Board of Directors of Catalent, Inc. He holds both a Bachelor of Science and an Honorary Doctorate in Electrical Engineering from the Milwaukee School of Engineering. He is a Member of the National Academy of Engineering (NAE) and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

    About Daniel Scavilla

    Mr. Scavilla has served as President and Chief Executive Officer of Globus Medical, Inc. (NYSE:GMED) since April 2022, leading Globus Medical's acquisition of NuVasive, Inc. and integrating the two organizations to create the second largest spine technology company in the world. Prior to that, Mr. Scavilla held various executive leadership positions at the company, including serving as its Chief Financial Officer. Prior to joining Globus Medical, Mr. Scavilla spent 28 years in increasing leadership roles within Johnson & Johnson, including roles across different businesses. Mr. Scavilla serves on Globus Medical's Board of Directors, and he previously served on the Board of Directors of Impulse Dynamics, a privately held medical technology company. Mr. Scavilla received a Bachelor of Science in Finance and Organizational Behavior from LaSalle University and a Master of Business Administration in International Management from Temple University.

    About Dentsply Sirona

    Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona's products provide innovative, high-quality, and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona's headquarters is located in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

    Contact Information

    Investors:

    Andrea Daley

    Vice President, Investor Relations

    +1-704-591-8631

    [email protected]

    Press:

    Marion Par-Weixlberger

    Vice President, Public Relations & Corporate Communications

    +43 676 848414588

    [email protected]



    Primary Logo

    Get the next $EXAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS
    $GE
    $GMED
    $XRAY

    CompanyDatePrice TargetRatingAnalyst
    Globus Medical Inc.
    $GMED
    1/30/2026$112.00Hold → Buy
    Needham
    Globus Medical Inc.
    $GMED
    1/27/2026$110.00Buy
    TD Cowen
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    Exact Sciences Corporation
    $EXAS
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    GE Aerospace
    $GE
    12/12/2025$386.00Buy
    Citigroup
    DENTSPLY SIRONA Inc.
    $XRAY
    12/9/2025$12.00Underweight
    Barclays
    GE Aerospace
    $GE
    12/4/2025$350.00Positive
    Susquehanna
    GE Aerospace
    $GE
    11/18/2025Underperform
    BNP Paribas Exane
    More analyst ratings

    $EXAS
    $GE
    $GMED
    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

    Passage of MCED legislation marks major milestone for early cancer detection Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with scientific innovation and patient need, this legislation represents a critical step toward addressing that unmet need and expanding access to this emerging

    2/3/26 2:32:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

    Milestone underscores test's significant role as a global standard-of-care in guiding personalized breast cancer treatment The predictive utility of this test helped an estimated 1.6 million patients safely avoid potentially unnecessary chemotherapy Economic models demonstrate improved outcomes and the potential for U.S. system-wide cost savings Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: more than two million breast cancer patients worldwide have now used the test to help guide treatment decisions. Backed by more than two decades of

    2/3/26 9:03:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Wellspect HealthCare Launches Surity™ Female External Catheter Improving Care for Women Living with Severe Urinary Incontinence

    MÖLNDAL, Sweden, Jan. 26, 2026 /PRNewswire/ -- Wellspect HealthCare, a global provider of continence care solutions, today announced the U.S. launch of the innovative Surity™ Female External Catheter, a new non-invasive solution designed to support women living with severe urinary incontinence. Wellspect HealthCare has been a trusted healthcare leader and at the forefront of innovation for more than 40 years, with established product brands including LoFric® and Navina™. Surity™ marks Wellspect's entry into a new category, bringing people suffering from severe urinary incontinence, and their caregivers, a reliable and comfortable urinary incontinence management solution.

    1/26/26 8:15:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Globus Medical upgraded by Needham with a new price target

    Needham upgraded Globus Medical from Hold to Buy and set a new price target of $112.00

    1/30/26 6:55:35 AM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Globus Medical with a new price target

    TD Cowen initiated coverage of Globus Medical with a rating of Buy and set a new price target of $110.00

    1/27/26 8:46:26 AM ET
    $GMED
    Medical/Dental Instruments
    Health Care

    Exact Sciences downgraded by Mizuho with a new price target

    Mizuho downgraded Exact Sciences from Outperform to Neutral and set a new price target of $105.00

    1/20/26 9:08:04 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Varon Leslie F bought $99,999 worth of shares (9,337 units at $10.71), increasing direct ownership by 19% to 57,343 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    11/25/25 5:26:33 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)

    4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    3/3/25 6:33:03 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Amendment: Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 8% to 66,730 units (SEC Form 4)

    4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

    1/29/25 6:14:01 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President Gowder Amy L sold $1,222,920 worth of shares (4,000 units at $305.73), decreasing direct ownership by 19% to 16,535 units (SEC Form 4)

    4 - GENERAL ELECTRIC CO (0000040545) (Issuer)

    2/3/26 4:52:39 PM ET
    $GE
    Consumer Electronics/Appliances
    Technology

    Senior Vice President Stokes Russell exercised 30,363 shares at a strike of $148.80 and sold $9,305,490 worth of shares (30,363 units at $306.47) (SEC Form 4)

    4 - GENERAL ELECTRIC CO (0000040545) (Issuer)

    2/3/26 4:50:35 PM ET
    $GE
    Consumer Electronics/Appliances
    Technology

    Vice President Giglietti Robert M. exercised 3,035 shares at a strike of $146.33 and sold $927,235 worth of shares (3,035 units at $305.51) (SEC Form 4)

    4 - GENERAL ELECTRIC CO (0000040545) (Issuer)

    2/3/26 4:48:52 PM ET
    $GE
    Consumer Electronics/Appliances
    Technology

    $EXAS
    $GE
    $GMED
    $XRAY
    SEC Filings

    View All

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/30/26 4:01:09 PM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form 10-K filed by GE Aerospace

    10-K - GENERAL ELECTRIC CO (0000040545) (Filer)

    1/29/26 6:32:04 AM ET
    $GE
    Consumer Electronics/Appliances
    Technology

    SEC Form DEFA14A filed by Exact Sciences Corporation

    DEFA14A - EXACT SCIENCES CORP (0001124140) (Filer)

    1/23/26 6:03:01 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Leadership Updates

    Live Leadership Updates

    View All

    Dentsply Sirona Appoints Donald Zurbay to Board of Directors

    CHARLOTTE, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced the appointment of Donald (Don) Zurbay to its Board of Directors (the "Board"), effective January 10, 2026. He will be joining the Board's Audit and Finance Committee. Mr. Zurbay brings extensive leadership experience in the dental and healthcare industries, and value creation across complex, global organizations. He most recently served as President and Chief Executive Officer (CEO) of Patterson Companies, following his tenure as Chief Financial Officer (CFO) from 2018 to 2022. During his tenure, Patterson maintained a longstanding dealer partnership

    1/13/26 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Dentsply Sirona Appoints Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization

    CHARLOTTE, N.C., Jan. 12, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY), the world's largest diversified manufacturer of professional dental products and technologies, today announced the appointment of Mark R. Bezjak as Group Vice President, Americas Regional Commercial Organization, effective January 28. The appointment supports Dentsply Sirona's continued focus on strengthening commercial execution, deepening customer relationships and accelerating growth across the Americas. Mr. Bezjak is a seasoned commercial executive with more than 20 years of experience leading large-scale, multi-billion-dollar organizations in the medical device

    1/12/26 9:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $EXAS
    $GE
    $GMED
    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

    SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    12/6/24 10:11:29 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

    SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

    11/14/24 1:22:35 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    $GE
    $GMED
    $XRAY
    Financials

    Live finance-specific insights

    View All

    Dentsply Sirona Declares Quarterly Cash Dividend

    CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 9, 2026, to holders of record as of December 26, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including den

    12/15/25 8:00:00 AM ET
    $XRAY
    Medical/Dental Instruments
    Health Care

    GE Aerospace Board of Directors Authorizes Regular Quarterly Dividend

    The Board of Directors of GE Aerospace (NYSE:GE) today declared a $0.36 per share dividend on the outstanding common stock of the Company. The dividend is payable January 26, 2026, to shareholders of record at the close of business on December 29, 2025. The ex-dividend date is December 29, 2025. About GE Aerospace GE Aerospace (NYSE:GE) is a global aerospace propulsion, services, and systems leader with an installed base of approximately 49,000 commercial and 29,000 military aircraft engines. With a global team of approximately 53,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and br

    12/4/25 2:56:00 PM ET
    $GE
    Consumer Electronics/Appliances
    Technology

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities